Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + pembrolizumab + temozolomide
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination involves **bevacizumab**, a monoclonal antibody targeting vascular endothelial growth factor (VEGF) to inhibit angiogenesis; **pembrolizumab**, a checkpoint inhibitor targeting PD-1 to enhance immune response; and **temozolomide**, an alkylating agent used in chemotherapy to kill cancer cells. The combination aims to treat glioblastoma by targeting both tumor growth and immune evasion.
02
Targets
Beyond the preview
Go deeper on bevacizumab + pembrolizumab + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + pembrolizumab + temozolomide.